InnovivaINVA
INVA
About: Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Employees: 112
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2,321% more call options, than puts
Call options by funds: $799K | Put options by funds: $33K
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
16% more capital invested
Capital invested by funds: $1.22B [Q2] → $1.41B (+$194M) [Q3]
3% more funds holding
Funds holding: 212 [Q2] → 218 (+6) [Q3]
10% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 83
2.39% less ownership
Funds ownership: 119.11% [Q2] → 116.72% (-2.39%) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for INVA.
Financial journalist opinion
Neutral
Business Wire
1 month ago
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States. "The licensing of Zevtera expands IST's diverse yet complementary portfolio of differentiated treatments.
Neutral
GlobeNewsWire
1 month ago
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US).
Neutral
Business Wire
2 months ago
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday,.
Neutral
Business Wire
2 months ago
Innoviva to Participate in the UBS Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at.
Neutral
Business Wire
2 months ago
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. “For the third quarter of 2024, we contin.
Neutral
Business Wire
3 months ago
Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data from three clinical abstracts and two oral presentations on the company's pipeline and Commercial portfolio during IDWeek 2024, October 16-19, 2024, in Los Angeles, CA. “Our clinical program continues to provide important findings from recent sub-analyses that add meaningful n.
Neutral
Business Wire
4 months ago
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Fo.
Neutral
Business Wire
6 months ago
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2024, and highlighted select corporate achievements. “Our robust second quarter continues to demon.
Positive
InvestorPlace
6 months ago
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
Everything is expensive these days including stocks. Amid a raging bull market, it is tough to find affordable stocks to buy.
Positive
InvestorPlace
7 months ago
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
Finding high-growth stock opportunities is crucial to constructing a stable and prosperous portfolio. Three outstanding businesses set up for remarkable development in 2024 are highlighted here.
Charts implemented using Lightweight Charts™